Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.59 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5968626 | 0.87 | CYP1A2 (0.62) | CYP1A2CYP2C19CYP3A4PDK1ATAD2 | |
| SCHEMBL17250001 | 0.87 | PPARA (0.53) | CYP1A2CYP2C19CYP3A4PDK1RAB9A | |
| SCHEMBL9036778 | 0.83 | LOXL2 (0.60) | CYP1A2CYP2C19CYP3A4PDK1ATAD2 | |
| SCHEMBL12591843 | 0.83 | KMT2A (0.64) | CYP1A2CYP2C19CYP3A4RAB9AMAPT | |
| SCHEMBL10220120 | 0.83 | ACACB (0.44) | CYP1A2CYP2C19CYP3A4PDK1ATAD2 | |
| SCHEMBL20306082 | 0.82 | PDK1 (0.45) | CYP1A2CYP2C19CYP3A4PDK1ATAD2 | |
| SCHEMBL13729470 | 0.81 | NPC1 (0.62) | CYP1A2CYP2C19CYP3A4PDK1RAB9A | |
| SCHEMBL23661 | 0.80 | TSHR (0.75) | CYP1A2CYP2C19CYP3A4PDK1ATAD2 | |
| SCHEMBL5550026 | 0.80 | CYP1A2 (0.57) | CYP1A2CYP2C19CYP3A4PDK1ATAD2 | |
| SCHEMBL798519 | 0.77 | RAB9A (0.67) | RAB9AMAPTNPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024033418-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | BACOBA AG (CH) | 2024-02-15 | — | — | WO | disclosed |
| EP-3471729-B1 | ISOXAZOLMETHYLTHIO-, THIENYLMETHYLTHIO- AND THIAZOMETHYLTHIO-DERIVATIVES FOR USE IN THE TREATMENT OF CANCER; VIRAL INFECTIONS; THROMBOTIC EVENTS OR PLATELET AGGREGATION | UNIV RUTGERS (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230022304-A1 | WDR5-MYC INHIBITORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| WO-2022256419-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20210300882-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-11028061-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-06-08 | — | — | US | disclosed |
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20180222874-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Bumham Prebys Medical Discovery Imstitute (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222874-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Bumham Prebys Medical Discovery Imstitute (US) | 2018-08-09 | — | — | US | disclosed |
| US-9458179-B2 | Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150322089-A1 | QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-12 | — | — | US | disclosed |
| US-9175285-B2 | Potent non-urea inhibitors of soluble epdxide hydrolase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140349368-A1 | POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785445-B2 | 7-phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8653273-B2 | Potent non-urea inhibitors of soluble epoxide hydrolase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120029022-A1 | Potent Non-Urea Inhibitors Of Soluble Epoxide Hydrolase | THE TRUSTEES OF COLUMBIA UNIVESITY IN THE CITY OF NEW YORK (US) | 2012-02-02 | — | — | US | disclosed |
| US-7968577-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100063051-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063051-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NFKB2, NFKBIA | CYP1A2 2171/4885CYP2C19 3875/4885CYP3A4 1887/4885 |
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | USP30, UCHL1, ADRM1 | CYP1A2 3131/4885CYP2C19 3933/4885CYP3A4 3151/4885 |
| US-20210300882-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | CYP1A2 3187/4885CYP2C19 4314/4885CYP3A4 2575/4885 |
| US-20180222874-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | CYP1A2 3187/4885CYP2C19 4314/4885CYP3A4 2575/4885 |
| US-20140349368-A1 | POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, ECE1 | CYP1A2 772/4885CYP2C19 1621/4885CYP3A4 764/4885 |
| US-20150322089-A1 | QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA2, CHRNA1 | CYP1A2 441/4885CYP2C19 1868/4885CYP3A4 1885/4885 |
| US-20120029022-A1 | Potent Non-Urea Inhibitors Of Soluble Epoxide Hydrolase | EPHX1, EPHX2, ECE1 | CYP1A2 772/4885CYP2C19 1621/4885CYP3A4 764/4885 |
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | SERPINC1, F12, RPL35 | CYP1A2 190/4885CYP2C19 162/4885CYP3A4 317/4885 |
| US-20230022304-A1 | WDR5-MYC INHIBITORS | MYC, WDR5, MYCBP | CYP1A2 4201/4885CYP2C19 4500/4885CYP3A4 4101/4885 |
| US-11028061-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | MYC, MYCBP, MLYCD | CYP1A2 3187/4885CYP2C19 4314/4885CYP3A4 2575/4885 |
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | PTGDR2, PTGDR, HRH2 | CYP1A2 155/4885CYP2C19 452/4885CYP3A4 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.